One of Wall Street’s best performing analysts sees strong long-term care growth for ACAD’s Nuplazid.
Joseph Foresi boosts his price target on SQ by $10 as the company captures more market share.
Wedbush: FB’s growth continues to fire up internationally, solidifying strong standing against competitors.
Roth Capital is impressed that SHOP’s model shows off scaled profitability in robust 3Q turnout.
Ed Arce lifts his price target on AUPH after recent R&D day widened doors to voclosporin’s opportunity.
Suji Desilva believes INTC is experiencing its best growth yet in data center segments.
Tim Chiang now sees a bigger per share value for ARDX’s tenapanor in the IBS-C market.
Oren Livnat expects MannKind’s inhaled insulin’s new label will be a real game-changer.
One analyst likes Nvidia’s stellar fall video game slate; top analyst cheers Intel’s improved Notebook sales.
Analyst praises Alnylam’s patisiran as best-in-class, even more confident in its safety and tolerability profile.